Physician profile
Jamie E Hitro
NPI 1356828230
$3,732.23
in general payments reported to CMS, 2019-2025
35 companies · $691 in 2025
The $691 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $733 · 2023: $1,123 · 2024: $793 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600 · Travel and Lodging: $7.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.78 |
| Travel and Lodging | $7.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $728.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $675.76 | 2021-2025 | |
| Lilly USA, LLC | $358.68 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $232.77 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $191.96 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $163.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neos Therapeutics, LP | $128.32 | 2022-2024 | Adzenys Xr-Odt |
| Pfizer INC. | $120.07 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $114.17 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $104.24 | 2023-2025 | Dyanavel Xr |
| Dexcom, INC. | $85.79 | 2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $83.59 | 2024-2025 | Apretude |
| Gilead Sciences, INC. | $78.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $71.98 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $70.68 | 2023-2025 | Pediarix, Bexsero, Rotarix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $68.00 | 2023-2024 | Quviviq |
| Amgen INC. | $44.78 | 2024-2025 | Otezla, Otezla, Repatha |
| Genentech USA, INC. | $41.36 | 2021-2022 | |
| Corcept Therapeutics | $35.48 | 2025 | Korlym |
| Ironshore Pharmaceuticals INC. | $32.53 | 2022-2024 | |
| Organon LLC | $32.10 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.91 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $29.58 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $24.96 | 2024 | Auvelity |
| Impel Pharmaceuticals INC. | $24.56 | 2022 | |
| Phadia US INC. | $19.76 | 2022 | |
| Seqirus USA INC | $19.17 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $17.25 | 2022 | |
| Esperion Therapeutics, INC. | $16.82 | 2023 | Nexletol |
| Hologic Sales and Service, LLC | $16.76 | 2023 | Aptima |
| Mayne Pharma Commercial LLC | $16.55 | 2024 | |
| Noven Therapeutics, LLC | $15.71 | 2025 | Xelstrym |
| Currax Pharmaceuticals LLC | $13.29 | 2022 | |
| Coopersurgical, INC. | $11.78 | 2022 | |
| Medline Industries LP | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Hitro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.